ReviewCurrent oncology reports2017
The Role of Hypofractionated Radiotherapy in Prostate Cancer.
Review in Current oncology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05120947 (A Phase I Study of Hypofractionated Adjuvant Radiotherapy for Resected Head and Neck Cancers), which is not on this map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I Study of Hypofractionated Adjuvant Radiotherapy for Resected Head and Neck Cancers (HART-HN)
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness of rectal displacement devices in managing prostate motion: a systematic review.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2021Pooled it
- Acute toxicity of image-guided hypofractionated proton therapy for localized prostate cancer.International journal of clinical oncology · 2018Trial
- Feasibility of longitudinal prostate RPhysics and imaging in radiation oncology · 2026Article
- Impact of intra- and interfractional motion on the dose distribution and urinary adverse events for magnetic resonance-guided prostate cancer radiotherapy.Physics and imaging in radiation oncology · 2026Article
- Prostate Stereotactic Body Radiotherapy With Synchrony®-Based Fiducial Tracking on Radixact® X9.Cureus · 2025Article
- Hypofractionated versus conventional fractionation external beam radiotherapy in intermediate and high risk localized prostate cancer.Discover oncology · 2024Article
- Pathologic response evaluation of localized or locally advanced esophageal carcinoma to induction chemotherapy followed by preoperative concurrent chemotherapy and hypofractionated radiotherapy: a clinical trial.Frontiers in oncology · 2024Article
- Optimal Bladder Volume for Hypofractionated Proton Therapy in Each Localized Prostate Cancer Risk Group.Cureus · 2023Article
- Hypofractionated Radiotherapy in Localized, Low-Intermediate-Risk Prostate Cancer: Current and Future Prospectives.Medicina (Kaunas, Lithuania) · 2023Review
- Impact of outpatient radiotherapy on direct non-medical cost in patients in the Central Macro Region of Peru 2021.Ecancermedicalscience · 2023Article
- Role of water in the crystal structure of LiPCDA monomer and the radiotherapy dose response of EBT-3 film.Medical physics · 2022Article
- Dose-Intensified Stereotactic Ablative Radiation for Localized Prostate Cancer.Frontiers in oncology · 2022Article
- Adaptive magnetic resonance-guided neurovascular-sparing radiotherapy for preservation of erectile function in prostate cancer patients.Physics and imaging in radiation oncology · 2021Article
- Review
- Article
- Neoadjuvant Treatment Options in Soft Tissue Sarcomas.Cancers · 2020Review
- Moderately HRT vs. CRT for localized prostate cancer using image-guided VMAT with SIB: evaluation of acute and late toxicities.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2020Article
- Automatic reconstruction of the delivered dose of the day using MR-linac treatment log files and online MR imaging.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2020Article
- RADIOTHERAPY OF PROSTATE CANCER: PRIMARY RADIOTHERAPY AND RADIOTHERAPY IN DISEASE RELAPSE.Acta clinica Croatica · 2019Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purpose of reviewIt is now accepted that prostate cancer has a low alpha/beta ratio, establishing a strong basis for hypofractionation of prostate radiotherapy. This review focuses on the rationale for hypofractionation and presents the evidence base for establishing moderate hypofractionation for localised disease as the new standard of care. The emerging evidence for extreme hypofractionation in managing localized and oligometastatic prostate cancer is reviewed. RECENT
findingsThe 5-year efficacy and toxicity outcomes from four phase III studies have been published within the last 12 months. These studies randomizing over 6000 patients to conventional fractionation (1.8-2.0 Gy per fraction) or moderate hypofractionation (3.0-3.4 Gy per fraction). They demonstrate hypofractionation to be non-inferior to conventional fractionation. Moderate hypofractionation for localized prostate cancer is safe and effective. There is a growing body of evidence in support of extreme hypofractionation for localized prostate cancer. Extreme hypofractionation may have a role in managing prostate oligometastases, but further studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.